| Literature DB >> 19837574 |
Laila Karra1, Beata Berent-Maoz, Micha Ben-Zimra, Francesca Levi-Schaffer.
Abstract
Downregulation of mast cells (MCs) function and/or survival is warranted in allergic inflammation (AI), mastocytosis/MC leukemias and in other inflammatory diseases in which MCs have a central role. Human MCs (hMCs) have been recently shown to express the death receptor (DR) TRAIL and the inhibitory receptors (IRs) CD300a and Siglec-8. TRAIL is the only known DR functional on hMCs, and interestingly its function is upregulated by IgE-dependent MC activation. The newly described IRs, CD300a and Siglec-8, potently downregulate MC activation and survival in vitro and inhibit different IgE-mediated responses in vivo. Therefore a selective targeting of TRAIL and of IRs on MC could be a novel immunopharmacological way to downregulate MC-associated diseases.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19837574 DOI： 10.1016/j.coi.2009.09.010
Source DB: PubMed Journal: Curr Opin Immunol ISSN： 0952-7915 Impact factor: 7.486